Festival of Biologics 2019, 15 – 17 October
LFB Biomanufacturing is a Contract Development and Manufacturing Organization (CDMO), located in Ales, belonging to LFB Group, and acting in the field of monoclonal antibodies and recombinant proteins.
It can offer mammalian cell line development capabilities with most common recombinant mammalian cell lines such as CHO. Moreover, LFB Biomanufacturing can propose the EMABling® platform using the proprietary YB2/0-E cell line to produce recombinant monoclonal antibodies having an enhanced antibody-dependent cellular cytotoxicity (ADCC) activity due to a specific glycosylation pattern. Combined with the host cell line YB2/0-E, specifically optimized expression vectors and cell culture medium, a powerful clone selection process, the EMABling® platform leads to gram-per-liter producing clones.
Upstream (USP) and downstream process (DSP) optimizations are executed in state-of-the-art facilities using both “platform-type” and customized approaches. LFB Biomanufacturing’s technological options are mainly focused on disposable equipment such as ambr® system, Wave or Single-Use Bioreactors (SUB). The GMP manufacturing offer, currently up to 1000 liters single use bioreactor, will be completed with 2000L bioreactors in 2020. Based on the strong experience of LFB for the selection of optimal chromatography and filtration/purification processes and viral clearance methods, LFB Biomanufacturing has a proven track record in tackling a number of challenging processes and scale-up, resulting in successful production of several antibodies and recombinant proteins.